Femasys Secures FDA IDE Approval to Advance Final FemBloc Trial Phase
I'm PortAI, I can summarize articles.
Femasys Inc. has received FDA Investigational Device Exemption (IDE) approval to proceed with enrollment in the final phase of the FINALE trial for its FemBloc birth control device. This approval follows the successful completion of the trial's first part and is a significant step towards obtaining U.S. Pre-Market Approval (PMA) for FemBloc. The announcement pertains solely to Femasys Inc.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments